Literature DB >> 10229321

Biologic characteristics of patients with hypocellular myelodysplastic syndromes.

R Goyal1, H Qawi, I Ali, S Dar, S Mundle, V Shetty, Y Mativi, K Allampallam, L Lisak, J Loew, P Venugopal, S Gezer, E Robin, S Rifkin, A Raza.   

Abstract

Rates of proliferation and apoptosis as well as expression of tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta) and the number of macrophages were measured in bone marrow (BM) biopsies of 33 patients who presented with hypocellular (cellularity < 30%) myelodysplastic syndromes (MDS). Results showed that 2/3 of the patients had high apoptosis, high cytokine levels and large number of macrophages in their biopsies while 1/3 did not. Apoptosis and TNF-alpha levels were directly related (r = 0.583, P = 0.003, n = 24) as was apoptosis and the degree of anemia (P = 0.033, n = 18). A subgroup of patients with abnormalities of chromosomes 5 or 7 had higher platelets (P = 0.026) and higher apoptosis (P = 0.038) when compared with the rest of the group. Eight patients had no evidence of apoptosis and almost no detectable TNF-alpha in their biopsies. We conclude that within the hypocellular variant of MDS, there may be two distinct sub-groups of patients, one who present with high cytokine-mediated intramedullary apoptosis and the other who may be better characterized as having a stem-cell failure defect since they showed no evidence of apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229321     DOI: 10.1016/s0145-2126(98)00187-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

1.  Diagnostic criteria to distinguish hypocellular acute myeloid leukemia from hypocellular myelodysplastic syndromes and aplastic anemia: recommendations for a standardized approach.

Authors:  John M Bennett; Attilio Orazi
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

Review 2.  The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Authors:  Amy E DeZern; Mikkael A Sekeres
Journal:  Oncologist       Date:  2014-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.